• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

TCPR_Benzodiazepines_May12.png

Benzos: Misunderstood, Misused — but Sometimes Just Right.

May 22, 2025
Daniel Carlat, MD

"The only thing that works for me is Xanax." "Can I get a 3-month script for Klonopin? My last doc didn't mind."
We’ve all heard versions of these.


Read More
1747611766342.jpeg

FDA Clears First Alzheimer's Blood Test—What's Actually New Here?

May 21, 2025
Daniel Carlat, MD

This week, the FDA cleared the first blood test for Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.It sounds like a big step forward. Maybe it will prove to be one. But after 22 years of Carlat Report coverage of overhyped tests and treatments, I’ve learned to pause before celebrating “firsts.”


Read More
3-Minute ADHD.jpeg

Choosing ADHD Meds: A 3 Minute Overview

May 21, 2025
Daniel Carlat, MD

ADHD pharmacology can feel overwhelming. Dozens of formulations. Conflicting data. High stakes for outcomes—and side effects. Each chapter of our Medication Fact Book starts with general tips, and I’m revising the ADHD section for our 8th edition.


Read More
Alpha2Thumb.png

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

October 18, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
Read More
TCPR_Print_and_Online.png

Choose Two Newsletters! Limited Time Special Discount Offer

October 16, 2024

We understand that you might not have time to read everything. That's why we're offering a special limited-time deal: subscribe to two newsletters of your choice and get 15% off the regular price!


Read More
Alpha2Thumb.png

Alpha-2 Agonists Review: Clonidine (Kapvay) and Guanfacine (Intuniv), Non-Stimulant ADHD Medications

October 6, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
Read More
What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg

What You Need to Know About Gepirone (Exxua) | Benefits, Side Effects, and Review of Trials

September 27, 2024
Chris Aiken, MD. and Greg Malzberg, MD
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists. 
Read More
shutterstock_1835827372.png
Commentary

8 Ways to Reduce Rework in Medication Preauthorizations

September 26, 2024
Lauretta Young, MD and Laurie Martin

Medication preauthorizations are essential but often frustrating, especially for psychiatric prescriptions. This article offers strategies to reduce revisions, ultimately streamlining the process.


Read More
Stimulant_Dosing_Thumb.jpg

Stimulant Dosing Limits for ADHD: When Is The Adderall / Ritalin Dose Too High?

September 18, 2024
Chris Aiken, MD., Kelvin Quiñones-Laracuente, MD, PhD, and Greg Malzberg, MD
 In this video, we aim to break down where the safe upper limits lie for stimulant dosing, what to consider when increasing doses, and why crossing certain thresholds can lead to serious risks. We start by discussing why increasing stimulant doses beyond a certain point can be dangerous.
Read More
Methylphenidate_thumb.jpg

L-Methylfolate May Offer Modest Boost to Antidepressants

September 4, 2024
Greg Malzberg, MD and Glen Spielmans, PhD.
In this video, we explore the potential of L-Methylfolate as a vital supplement in depression treatment. L-Methylfolate is a form of folate, a naturally occurring B-vitamin, and is often used to enhance the effects of traditional antidepressants.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.